Therefore, in this study, we sought to model AGS using iPSCs carrying the IFIH1 R779H mutation to investigate the pathophysiology of the disease and identify potential therapeutic agents that could modulate excessive IFN signaling before irreversible damage occurs. The gene discussed is IFNA1; the disease is Aicardi-Goutieres syndrome.